三元基因(837344) - 2025 Q1 - 季度财报

Financial Performance - Net profit attributable to shareholders for Q1 2025 was CNY -12,250,556.92, representing a decline of 735.27% year-over-year [12]. - Operating revenue for Q1 2025 was CNY 45,021,673.04, down 6.11% from the same period in 2024 [12]. - The company's basic earnings per share for Q1 2025 was CNY -0.10, a decrease of 600.00% year-over-year [12]. - Total revenue for Q1 2025 was CNY 45,021,673.04, a decrease of 6.06% compared to CNY 47,952,373.12 in Q1 2024 [51]. - Net profit for Q1 2025 was a loss of CNY 12,250,556.92, compared to a profit of CNY 1,928,398.18 in Q1 2024 [52]. - The company reported a total comprehensive loss of ¥11,980,741.88 for Q1 2025, compared to a comprehensive income of ¥2,427,166.30 in Q1 2024 [56]. Assets and Liabilities - Total assets as of March 31, 2025, were CNY 1,199,269,643.07, a decrease of 2.44% compared to the end of 2024 [12]. - The total liabilities as of March 31, 2025, were CNY 590,699,872.29, down from CNY 608,480,109.76 at the end of 2024 [47]. - The company’s total liabilities to assets ratio was 49.25% as of March 31, 2025, slightly down from 49.50% at the end of 2024 [12]. - The total value of assets under mortgage is 554,848,109.29, which accounts for 46.26% of the total assets [28]. - The company's non-current assets totaled CNY 996,029,678.91 as of March 31, 2025, slightly up from CNY 989,433,003.73 at the end of 2024 [46]. Cash Flow - The net cash flow from operating activities was CNY 699,774.62, a significant decrease of 95.41% compared to the previous year [14]. - Operating cash flow for Q1 2025 was ¥699,774.62, a decrease of 95.42% from ¥15,256,581.97 in Q1 2024 [57]. - The ending cash and cash equivalents balance decreased to $83,274,038.58 from $153,656,838.74, reflecting a decline of about 45.8% [59]. - The net increase in cash and cash equivalents was -$25,839,694.76, worsening from -$20,401,204.55 [59]. Research and Development - Research and development expenses increased by 199.95% to CNY 8,773,200.96, driven by clinical trials for new products [14]. - The company plans to continue investing in R&D for new therapies, indicating a focus on market expansion and innovation [14]. - The company has ongoing new drug research and development projects, increasing investment in R&D to support long-term growth [30]. - The company incurred R&D expenses of ¥8,773,200.96 in Q1 2025, significantly higher than ¥2,924,856.44 in Q1 2024, reflecting increased investment in innovation [53]. Shareholder Information - The total number of unrestricted shares is 113,560,796, accounting for 93.23% of the total share capital [18]. - The total share capital is 121,810,000 shares, with 6,422 common shareholders [18]. - The largest shareholder, Beijing Southeast Pharmaceutical Investment Holdings Co., Ltd., holds 46,907,925 shares, representing 38.51% of the total shares [20]. Operational Developments - The company has completed Phase III clinical trials for human interferon α1b nebulization treatment for pediatric RSV pneumonia, demonstrating significant improvement in key clinical symptoms such as respiratory distress [31]. - The new PEG-integrated interferon mutant injection combined with genetic testing aims to significantly increase the clinical cure rate for chronic hepatitis B, with 791 subjects enrolled in the clinical study [32][33]. - The company has successfully launched the antiviral oral spray (brand name: Lishuxing®), enhancing its market competitiveness in disinfection products and expanding its product line [36]. - The company is advancing the γδT cell tumor immunotherapy project, focusing on developing cost-effective "off-the-shelf" cell therapy products for various cancers, including acute and refractory leukemia [39]. Strategic Initiatives - The company is constructing a smart production and R&D base aimed at achieving "Industry 4.0" standards in biopharmaceuticals, which will support new product launches and contract development manufacturing (CDMO) services [40]. - The company has enhanced its digital operations, improving the efficiency of various information systems, including SCADA, DCS, MES, and others, leading to better overall equipment effectiveness (OEE) and compliance in production [41]. - A new generation of equipment management information system has been successfully launched, establishing a comprehensive lifecycle management system for production line equipment, which significantly improves management efficiency and production capacity [42].